PECULIARITIES OF THE COURSE HEPATITIS B AND C INFECTIONS IN HEMODIALYSIS PATIENTS: A LITERATURE REVIEW

Arina Yespotayeva, Kairat Kabulbayev, Аlmagul Kurmanova, Abduzhappar Gaipov, Nersesov Alexander Vitalevich, Abai Shepetov, Gulnar Chingayeva, Nagima Mustapayeva, Gainutdin Aisulu Ermekovna

2025

Closed access Metadata (CSL-JSON)

DOI 10.26212/2227-1937.2025.83.21.004

Data confidence 70 medium

How this score is calculated

It is built from checkable properties of the record itself: whether the article has a DOI, how many independent sources confirmed its data, whether the required fields are filled in, and how recent the latest confirmation is. Disagreement between sources and a missing identifier lower it. A value of 80 or above means the record was published without further checking; 60 to 79 means it is published at reduced confidence, with a manual check advisable. A record verified by an editor by hand is never pushed below 90 by a recalculation. This scores our data about the article, not the article itself.

Abstract

Background. Hepatitis B (HBV) and Hepatitis C (HCV) present significant challenges for hemodialysis patients due to impaired immunity and frequent blood exposures. Advancements in antiviral therapies, infection control measures, and vaccination are critical for reducing their burden. Purpose of the review. To evaluate the epidemiology, management, and prevention of HBV and HCV in hemodialysis patients. The review synthesized current research on transmission, infection control, antiviral therapies, and vaccination strategies, emphasizing their role in improving patient outcomes. Materials and methods. A systematic review of PubMed, Google Scholar, and Cochrane Library (2000–2022) using keywords like «Hepatitis B,» «Hepatitis C,» «Hemodialysis,» «Infection Control,» and «Vaccination.» Conclusions: HBV and HCV remain critical concerns in hemodialysis settings. Advances in therapy, combined with preventive measures, are essential for better patient outcomes and infection control.